Status:
COMPLETED
Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Esophageal Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, inc...
Eligibility Criteria
Inclusion
- Patients with esophageal cancer who received definitive radiotherapy (radiotherapy dose ≥50Gy) from 2015 to 2016
- Age ≥ 18
- The radiation field included primary esophageal tumor with or without lymph node metastasis
Exclusion
- Radiotherapy dose \< 50Gy
- Palliative radiotherapy
- The radiation field are metastatic areas, such as bone, brain, adrenal gland, isolated metastatic lymph nodes, etc
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2021
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05194371
Start Date
June 1 2021
End Date
December 15 2021
Last Update
January 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, China, 100021